NEUROCRINE BIOSCIENCES INC (NBIX)       108.22  -2 (-1.81%)

Company Profile

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 900 full-time employees. The firm is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.

Company Info

NEUROCRINE BIOSCIENCES INC

12780 El Camino Real

San Diego CALIFORNIA 92130

P: 18586177600.0

CEO: Kevin C. Gorman

Employees: 900

Website: https://www.neurocrine.com/